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ABSTRACT  
Atypical teratoid rhabdoid tumor (ATRT) is a fatal pediatric malignancy of the central neural 
system lacking effective treatment options. It belongs to rhabdoid tumor family usually caused by 
biallelic inactivation of SMARCB1, encoding a key subunit of SWI/SNF chromatin remodeling 
complexes. Previous studies proposed that SMARCB1 loss drives rhabdoid tumor by promoting 
cell cycle through activating transcription of cyclin D1 while suppressing p16. However, low 
cyclin D1 protein expression is observed in most ATRT patient tumors. The underlying 
mechanism and therapeutic implication of this molecular trait remain unknown. Here, we show 
that SMARCB1 loss in ATRT leads to the reduction of cyclin D1 expression by 
upregulating MIR17HG, a microRNA (miRNA) cluster known to generate multiple miRNAs 
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targeting CCND1. Furthermore, we find that this cyclin D1 deficiency in ATRT results in 
marked in vitro and in vivo sensitivity to the CDK4/6 inhibitor palbociclib as a single agent. Our 
study identifies a novel genetic interaction between SMARCB1 and MIR17HG in regulating 
cyclin D1 in ATRT and suggests a rationale to treat ATRT patients with FDA-approved CDK4/6 
inhibitors. 
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INTRODUCTION  
 SMARCB1-deficient rhabdoid tumors are a family of histologically and genetically related 
childhood-onset malignancies [1]. While rhabdoid tumors can arise in soft tissues anywhere in the 
body, they are most frequently found in central nervous system (CNS), where they are referred to 
as atypical teratoid rhabdoid tumors (ATRTs) [1]. Approximately 90% of ATRT cases are 
diagnosed in children under three years of age. Despite current aggressive standard treatments 
including surgery, radiation therapy and high-dose chemotherapy with stem cell transplant, most 
ATRT patients succumb to their disease within one year of diagnosis [1,2]. Thus, identifying 
druggable vulnerabilities of ATRT is of critical need in order to devise safe and effective 
treatments.  
ATRTs are driven by biallelic inactivating mutations of the tumor-suppressor gene 
SMARCB1 (SNF5) [3,4], which encodes a key component of SWI/SNF ATP-dependent chromatin 
remodeling complexes [5,6]. SWI/SNF complexes are polymorphic assemblies of 15 subunits, 
including a catalytic ATPase subunit, either SMARCA4 or SMARCA2 (BRM), and a variety of 
associated proteins including SMARCB1 [5,6]. They are known to interact with tissue-specific 
transcription factors, thus regulating gene expression in a context-dependent manner [5,6].  
Similar to ATRT, the closely related non-CNS malignant rhabdoid tumor (MRT), which 
arises most commonly in the kidney, is also attributed to SMARCB1 loss [3,4]. Gene expression 
profiling of ATRTs and non-CNS MRTs has shown that they are biologically similar tumors 
arising in different tissues [7]. However, recent genome-wide profiling studies have revealed 
This article is protected by copyright. All rights reserved.
 6 
distinct subgroups with different genetic and epi-genetic identities within both ATRTs and non-
CNS MRTs [8–14], highlighting the complexity of these related tumors.  
Forced SMARCB1 expression in an abdomen-derived MRT cell line MON was shown to 
result in cell cycle arrest by repressing transcription of CCND1 encoding cyclin D1 [15], which 
activates CDK4/6, thereby promoting cell cycle progression [16]. Genetic ablation of cyclin D1 in 
mice that were heterozygous for Snf5 loss suppressed formation of rhabdoid tumors [17]. 
Furthermore, a microarray study showed that brain-derived rhabdoid tumors (n=11) expressed 
higher levels of CCND1 compared to normal cerebellum and medulloblastomas [18]. These 
observations suggest that SMARCB1 loss might drive rhabdoid tumors by up-regulating 
expression of cyclin D1 [6].  
However, this SMARCB1-mediated cyclin D1 repression has not been observed in other 
MRT cell lines such as kidney-derived G401 and muscle-derived A204[19,20]. Ectopic 
SMARCB1 expression in A204 cells resulted in upregulation of cyclin D1 protein [19]. 
Furthermore, CCND1 expression in 40 extracranial MRTs was significantly reduced when 
compared to human embryonic stem cells (hESCs) in a recent RNA-seq analysis [9]. Therefore, 
the relationship between SMARCB1 and cyclin D1 in rhabdoid tumors remains unclear.  
We previously undertook an immunohistochemistry (IHC) study of 25 ATRT patient 
tumors and found that 80% of these tumors showed no evidence of cyclin D1 expression [21]. 
These findings in this large ATRT collection suggested that SMARCB1 loss may impact cyclin 
D1 expression through post-transcriptional mechanisms. Indeed, cyclin D1 is frequently 
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dysregulated in cancers and its expression levels can be regulated both transcriptionally and post-
transcriptionally [22,23]. Although the protein-level data was clear, the underlying mechanism of 
cyclin D1 deficiency in ATRT remained to be elucidated. 
While SMARCB1 inactivation accounts for 98% of ATRT cases, the other 2% are caused 
by deleterious mutations in SMARCA4 [24]. We and others discovered that biallelic inactivating 
mutations in SMARCA4 underlie small cell carcinoma of the ovary, hypercalcemic type 
(SCCOHT), a rare and often lethal cancer of young women [25–28]. While SCCOHT and ATRT 
clearly arise from two distinct organs, they resemble each other at the morphological level 
including the presence of rhabdoid cells (i.e. cells with eccentric nuclei and abundant eosinophilic 
cytoplasm) [29,30]. Similar to ATRT, SCCOHT also harbors few other genetic alterations as 
indicated by whole exome sequencing studies [25,26,28]. Furthermore, global DNA methylation 
analysis in SCCOHT and ATRT suggests that they also share similar epigenomic signatures [31]. 
We recently uncovered that SMARCA4 directly activates CCND1 transcription and SMARCA4 
loss in SCCOHT and non-small cell lung cancer (NSCLC) results in cyclin D1 deficiency; this 
leads to exquisite sensitivity to CDK4/6 inhibitors including palbociclib, abemaciclib and 
ribociclib [32,33], approved by the U. S. Food and Drug Administration (FDA) for treating a 
subtype of breast cancer [34–36]. Given the remarkable similarities between ATRT and SCCOHT 
described above, we postulated that cyclin D1 protein deficiency in ATRT [21] may also result in 
vulnerability to CDK4/6 inhibition. 
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 In this study, we sought to investigate the underlying mechanisms of cyclin D1 deficiency 
in ATRT and explored the potential utility of the CDK4/6 inhibitor palbociclib in targeting this 
lethal cancer affecting infants and young children. 
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MATERIALS AND METHODS 
Cell culture and Viral Transduction 
BT12 and CHLA-266 cell lines were provided by Children’s Oncology Group Cell 
Culture/Xenograft Repository. CHLA-05, CHLA-02, CHLA-04 and CHLA-06 are low passage 
ATRT cell lines developed from pediatric ATRT tumors resected at Children's Hospital Los 
Angeles (Los Angeles, CA, USA). BT16 was generously donated by Dr. P. J. Houghton 
(Nationwide Childrens Hospital, Columbus, OH, USA). NHA was from Dr. N. Jabado (McGill 
University, Montreal, Quebec, Canada) originally from A. Guha (Labbatt brain tumor center, 
Toronto, ON, Canada). All cell lines were maintained at 37 °C in 5% CO2. All cell lines were 
validated by STR profiling and regularly tested for Mycoplasma using Mycoalert Detection Kit 
(Lonza, Basel, Switzerland). See supplementary material, Supplementary materials and methods 
for details of cell culture.  
 
All experiments with ectopic expression and shRNA knockdown were performed using lentiviral 
transduction following http://www.broadinstitute.org/rnai/public/resources/protocols. Infected 
cells (30 h post-infection) were selected using antibiotics for 2–4 days and harvested immediately 
for experiments.  
 
siRNA transfection 
mirVana® miRNA inhibitor against miR-19a (product ID:MH10649) and miR17 (product 
ID:MH12412) were purchased from ThermoFisher (Waltham, MA, USA). BT12 and CHLA-06 
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cells were transfected with these inhibitors at a final concentration of 20 nM using Lipofectamine 




Individual shRNA vectors used were from the Mission TRC library (Sigma, St. Louis, MO, USA) 
provided by the Genetic Perturbation Service (GPS) of Goodman Cancer Research Centre and 
Biochemistry at McGill University: shCCND1#1 (TRCN0000295876), shCCND1#2 
(TRCN0000288598), shSMARCB1 #1 (TRCN0000010503), shSMARCB1 #2 
(TRCN0000298820). pLX304-GFP, pLX304-CCND1, pLX317-GFP, pLX317-CDK4, pLX317-
SMARCB1 were obtained from TRC3 ORF collections from TransOMIC and Sigma provided by 
the GPS. MIR17HG was amplified from pcDNA3.1/V5-His-TOPO-mir17-92[37] and cloned into 
pPrimer-FF1. The plasmid pcDNA3.1/V5-His-TOPO-mir17-92 was provided by T. Duchaine 
(McGill University) and was originally from Dr. Joshua T. Mendell, University of Texas 
Southwestern Medical Center).  
 
Compounds and antibodies 
Palbociclib (S1116) was purchased from Selleck Chemicals (Houston, TX, USA). Antibodies 
against HSP90 (H-114), Cyclin D1 (A12), CDK6 (C-21), CDK4 (DCS-35) and p16 (C-20) were 
from Santa Cruz Biotechnology (Dallas, TX, USA); antibodies against p-RB (S795), PTEN 
(9188S) and Bim (2933S) were from Cell Signaling Technology (Danvers, MA, USA); antibody 
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against SMARCB1 (A301-087A) was from Bethyl Laboratories (Montgomery, TX, USA). 
Antibody against Rb (554136) was from BD Pharmingen (San Jose, CA, USA). Antibodies used 
for immunohistochemistry are listed in the method section below.  
 
Immunohistochemistry of patient tumor samples and automated quantification  
Three TMAs used were previously described: 36 AT/RTs [21], 59 HGSC and 32 SCCOHTs [33]. 
Studies were approved by the Institutional Review Board (IRB) of Children’s Hospital of 
Philadelphia (ATRT), Jewish General Hospital (HGSC) and McGill University (SCCOHT). 
ATRT samples were obtained retrospectively from archival pathology material from deceased 
patients (no informed consent was obtained) after IRB approval, with all identifiers removed. 
Informed consent was obtained from all HGSC and SCCOHT participants. See supplementary 
material, Supplementary materials and methods for details.  
 
Colony formation assays 
Since different cell lines have variable proliferation rates and sizes, plating densities were first 
optimized to allow ~2 weeks of drug treatment, before reaching 90% confluency. Single cell 
suspensions were then counted and seeded into 6-well plates with optimized densities (2–8x104 
cells/well). Cells were treated with vehicle control or drugs on the following day and culture 
medium was refreshed every 3 days. At assay endpoints, cells were fixed with 3.75% 
formaldehyde, stained with crystal violet (0.1% w/v) and photographed. All relevant assays were 
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performed independently at least three times.  
 
Cell viability assays 
Cells were seeded into 96-well plates (1000–2,000 cells per well). Twenty-four hours after seeding, 
CDK4/6 inhibitors were added to final drug concentrations ranging from 0.0026–10 µM. Cells 
were then incubated for 5–7 days and viability was measured using the CellTiter-Blue assay 
(Promega, Madison, WI, USA). Relative survival of treated cells was normalized to the untreated 
controls after background subtraction. 
 
Protein lysate preparation and immunoblots 
Cells were first seeded in normal medium without drug. The medium was replaced next day with 
or without drug as indicated. After drug stimulation, cells were washed with cold PBS, lysed with 
protein sample buffer and processed with Novex® NuPAGE® Gel Electrophoresis Systems 
(Invitrogen).  
 
RNA isolation and RT-qPCR 
Cells seeded a day before were harvested for RNA isolation using Trizol (Invitrogen). Synthesis 
of cDNAs using Maxima First Strand cDNA Synthesis Kit (Thermo Scientific) and RT-qPCR 
assays using SYBR® Green master mix (Roche) or Taqman probes for miRNAs (Thermo Fisher) 
were performed according to manufacturer protocols. Relative mRNA levels of each gene shown 
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were normalized to the expression of the house keeping gene GAPDH. The sequences of the 
primers are listed in supplementary material, Supplementary materials and methods for details. 
 
Cell line RNA-Seq 
Total RNA from cell lines was extracted with RNeasy Mini Kit (Qiagen, Hilden, Germany) and 
quality controlled and subjected for RNA-seq at Genome Quebec (Montreal, Quebec, Canada). 
Data analysis were performed as previously described [33]. See supplementary material, 
Supplementary materials and methods for details.  
 
Chromatin Immunoprecipitation (ChIP) 
Sixty million BT12 cells were fixed in complete media containing 0.3% formaldehyde for 30 
minutes at 4 °C and then quenched with 0.125M glycine for 5 min. Fixed cells were pelleted and 
washed twice with PBS before snap-freezing on dry ice. Antibody against SMARCB1 (Abcam, 
12167) was used for ChIP experiments by following a protocol using MNase [38]. The 
sequences of primers used for RT-qPCR assays are listed in supplementary material, 
Supplementary materials and methods.  
 
Mouse intracranial tumor model and in vivo drug studies 
All procedures involving animals were performed in accordance with the guidelines of the 
Canadian Council of Animal Care and the Animal Utilization Protocols, approved by the 
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Institutional Animal Care Committee at McGill University Health Centre Research Institute and 
McGill University. 
The ATRT-derived cell line CHLA-06, expressing Firefly Luciferase, was used to generate 
intracranial orthotopic tumors in scid/IL2Rgnull mice (NSG,005557, NOD-scid/IL2Rgnull, NSG, 
Jackson Laboratories, Bar Harbor, ME, USA) essentially as described previously [39]. Mice were 
also imaged twice per week using an IVIS 200 Imager (Perkin Elmer, USA) after intraperitoneal 
injection of 150 mg/kg of D-luciferin (Firefly, potassium salt, Caliper Life Sciences, Waltham, 
MA, USA). Mice received palbociclib 150 mg/kg/day or placebo/vehicle (50 mM sodium L-lactate 
buffer pH 4.0) in the 200 µl volume administered by oral gavage. See supplementary material, 
Supplementary materials and methods for details.  
 
Statistical analyses 
Statistical significance was calculated using two-tailed Student’s t-tests, two-way ANOVA or non-
parametric Mann–Whitney tests. Prism software (GraphPad Inc, San Diego, California, USA) was 
used to generate graphs and statistical analyses. Error bars show standard deviation (SD) or 
standard error of the mean (s.e.m.). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. 
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RESULTS  
Cyclin D1 deficiency in ATRT is caused by SMARCB1 loss 
Our previous IHC study of 25 SMARCB1-deficient ATRT patient tumors found that 80% 
of these cases showed absence of cyclin D1 protein expression [21]. To further confirm this finding, 
we employed unbiased automated quantification [40] to re-analyze published IHC data of 25 
AT/RT samples [21] and 10 additional unpublished cases (n = 35), along with ovarian high grade 
serious carcinomas (HGSC; n = 52) and SCCOHT tumors (n = 32) which served as positive and 
negative staining controls respectively due to their known cyclin D1 status [33]. Identical IHC 
antibody and protocols were used for all tumors to allow direct comparison. Similar to SCCOHTs, 
cyclin D1 IHC signal was negative in most ATRTs (Figure 1A, B). Furthermore, ATRTs were 
generally RB-proficient and p16-deficient, which resembles SCCOHTs and is the reverse of 
HGSCs (Figure 1A, B). The p16 deficiency in ATRT is consistent with previous studies showing 
that SMARCB1 activates CDKN2A transcription [41]. These data confirm and extend our previous 
findings of cyclin D1 protein deficiency in ATRT [21]. 
Recent studies classified ATRT into three subtypes (TYR, SHH and MYC) based on DNA 
methylation and gene expression profiling [10,12–14].  We analyzed the cyclin D1 protein 
expression in a panel of ATRT cell lines (BT12, CHLA-226, CHLA-06, CHLA-05, CHLA-02, 
CHLA-04 and BT16), representing different ATRT subtypes as defined by recent studies 
[10,12,13]. Consistent with our above observations in patient derived tumors, western blot analysis 
shows that these ATRT cell lines expressed lower levels of cyclin D1 and p16 protein compared 
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to NHA, a non-transformed human astrocyte cell line (Figure 1C).  Since recent studies suggest 
that ATRT subtypes may originate from different precursor cells [8,10–13], NHA may not be the 
perfect control for all subtypes. Therefore, it was important to compare cyclin D1 expression in 
isogenic ATRT cell pairs engineered to differ only in SMARCB1 status. Similar to previous 
studies in non-CNS MRT cells [15,19,42], SMARCB1 restoration in all ATRT cell lines tested 
(BT12, CHLA-226, CHLA-06, CHLA-02 and BT16) resulted in strong growth inhibition 
(supplementary material, Figure S1) and elevated p16 expression (Figure 1D). However, cyclin 
D1 expression was strongly elevated in these SMARCB1-restored ATRT cell lines (Figure 1D). 
Complementary to these findings, knockdown of SMARCB1 in NHA cells using two independent 
shRNAs strongly suppressed cyclin D1 expression (Figure 1E). Together, these data suggest that 
SMARCB1 loss in ATRT reduces cyclin D1 protein expression. 
 
SMARCB1 suppresses MIR17HG expression in ATRT 
SMARCA4 loss leads to strong downregulation of CCND1 transcription through impacting 
chromatin structure at its gene locus in both SCCOHT and NSCLC[32,33]. Considering the 
similarities between SCCOHT and ATRT [30], we investigated whether this potential mechanism 
is operative in cyclin D1 regulation by SMARCB1 in ATRT. In contrast to SCCOHT and NSCLC, 
SMARCB1 restoration only results in a mild upregulation (~1.5–2-fold) of CCND1 mRNA 
expression (supplementary material, Figure S2), suggesting additional post-transcriptional 
regulation. To uncover the underlying mechanism, we performed transcriptome analysis of two 
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commonly used ATRT cell lines, CHLA-06 (suspension) and BT12 (adhesive), with or without 
SMARCB1 restoration using RNA-sequencing (RNA-seq). We identified 632 up-regulated and 
158 down-regulated common genes as result of SMARCB1 restoration in both cell line pairs 
(Figure 2A, supplementary material, Table S1). This is consistent with the role of SWI/SNF 
complex that can function as both transcription activator or suppressor [43]. To help identify the 
potential direct targets of SMARCB1 among these candidates, we compared this list with genes 
whose loci showed SMARCB1 occupancy within 100 kbp from their transcription start sites from 
a published chromatin immunoprecipitation sequencing (ChIP-seq) study in SMARCB1-proficeint 
HeLa cells [44]. We rationalized that this endogenous SMARCB1 ChIP-seq study in HeLa cells 
may help identify SMARCB1 target genes conserved among different cell types. This analysis 
identified 20 candidate genes out of which 11 were upregulated and 9 were downregulated upon 
SMARCB1 restoration in ATRT cells (Figure 2B).  
Among these candidates, MIR17HG is particularly interesting as it has been previously 
linked to post-transcriptional regulation of cyclin D1 which may explain our above observations 
in ATRT (Figure 1). MIR17HG encodes a cluster of 6 miRNAs (miR-17 – 92), 3 out of which 
(miR-19a, miR-17 and miR-20a) have been shown to target cyclin D1 [45–48]. miRNAs are small 
non-coding RNAs of 20–22 nucleotides that inhibit gene expression by repressing translation but 
also accelerating mRNA degradation [49]. Verifying our RNA-seq results, RT-qPCR analysis 
showed that MIR17HG is significantly suppressed upon SMARCB1 restoration in BT12 and 
CHLA-06 cells (Figure 2C). Additional published ChIP-seq data sets also showed an enrichment 
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of SMARCB1 occupancy in the promoter region of MIR17HG in NCCIT and HepG2 cells (Figure 
2D) [50–52]. In SMARCB1-restored BT12 cells, our ChIP-PCR detected significant SMARCB1 
occupancy at the MIR17HG promoter but not at an upstream region of MIR17HG locus (Figure 
2E). Together, these data indicate that SMARCB1 loss activates MIR17HG by directly interacting 
with its gene locus, which may contribute to the reduced cyclin D1 expression in ATRT cells.  
 
MIR17HG contributes to cyclin D1 deficiency induced by SMARCB1 loss in ATRT 
To evaluate the role of MIR17HG in regulating cyclin D1 expression, we knocked down 
MIR17HG with two independent shRNAs in three ATRT cell line BT12, CHLA-06 and BT16 
(Figure 2F, supplementary material, Figure S3A). Cyclin D1 was upregulated at both mRNA and 
protein levels in all cell lines (Figure 2F,G, supplementary material, Figure S3B,C), mirroring the 
role of miRNAs in inducing mRNA degradation and inhibiting translation [49]. While it is possible 
that any of the six miRNAs encoded by MIR17HG may contribute to cyclin D1 regulation, we 
focused on miR-17 and miR-19a which have been shown to target CCND1 mRNA [45–48]. As 
expected, their inhibition led to elevation of cyclin D1 mRNA and protein expression in BT12 and 
CHLA-06 cells (supplementary material, Figure S4). However, MIR17HG suppression had little 
effect on the expression of PTEN and BIM, known targets of this miRNA cluster characterized in 
other cancers [53,54] (supplementary material, Figure S5), likely due to context dependency of 
miRNA regulation [55]. Nevertheless, these data confirmed that MIR17HG plays a key role in 
determining cyclin D1 expression in ATRT.  
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To investigate the contribution of MIR17HG to SMARCB1-mediated cyclin D1 regulation, 
we performed rescue experiments where MIR17HG was ectopically expressed in ATRT cells with 
or without SMARCB1 restoration. The expression of mature miR-19a, known to target cyclin D1 
in several other contexts [46,48], was measured as a read out for effective processing of exogenous 
MIR17HG.  In line with Figure 2C, SMARCB1 restoration suppressed miR-19a in both BT12 and 
CHLA-06 cells (Figure 2H). Ectopic expression of MIR17HG in SMARCB1-restored ATRT cells 
led to expected increase in miR-19a expression and contaminant suppression of SMARCB1-
induced cyclin D1 upregulation, at both mRNA and protein levels (Figure 2H, I). Supporting this, 
MIR17HG-mediated regulation of cyclin D1 in ATRT, CCND1 mRNA tends to be inversely 
correlated with MIR17HG expression in our cell line panel (supplementary material, Figure S6). 
Furthermore, in a previous study classifying ATRT patient tumors into three subtypes (TYR, MYC 
and SHH) [10], we observed an inverse association between MIR17HG and CCND1 mRNA 
expression among these subtypes (Figure 2J). Collectively, these data suggest that SMARCB1 loss 
results in cyclin D1 deficiency in ATRT at least in part through elevating MIR17HG expression 
(Figure 2K).  
 
Cyclin D1 deficiency causes sensitivity of ATRT to CDK4/6 inhibition both in vitro and in 
vivo 
We recently showed that cyclin D1 deficiency induced by SMARCA4 loss constrains 
CDK4/6 kinase activity, which leads to susceptibility to CDK4/6 inhibition in multiple cancer 
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types [32,33]. Given that ATRT is also deficient in cyclin D1 protein expression via a different 
mechanism, we investigated the drug sensitivities of ATRT to CDK4/6 inhibition. While pan-CDK 
inhibitor showed efficacy in targeting MRT [56,57], highly selective CDK4/6 inhibitors such as 
palbociclib have not been evaluated as single agents to target ATRT. We found that ATRT cells, 
but not NHA controls, are highly sensitive to palbociclib in both long-term colony formation and 
short-term cell viability assays (Figure 3A,B). Consistently, phosphorylation of RB, a direct target 
of CDK4/6, was significantly inhibited in ATRT cells but not NHA cells (Figure 3C). To evaluate 
the efficacy of palbociclib in treating ATRT in vivo, we generated an orthotopic mouse model 
where CHLA-06 cells (labelled with luciferase for visualizing tumor burden in live animals) were 
intracranially engrafted into brains of immunodeficient mice. As shown in Figure 3D,E palbociclib 
treatment of established tumors resulted in potent inhibition of tumor-related bioluminescence, 
indicating a strong therapeutic response for palbociclib as a single agent. 
To investigate the contribution of cyclin D1 deficiency to palbociclib response in ATRT, 
we ectopically overexpressed cyclin D1 in two ATRT cell lines CHLA-06 and BT12. As shown 
in Figure 3F–I, cyclin D1 ectopic expression increased RB phosphorylation and conferred 
substantial resistance to palbociclib in both cell lines. In contrast, overexpression of the target of 
palbociclib, CDK4, did not confer resistance suggesting that cyclin D1 is the rate limiting factor. 
In keeping with this, knock down of cyclin D1 in BT12, which express higher levels of cyclin D1 
compared to other ATRT cell lines (Figure 1C), further sensitized these cells to palbociclib 
treatment (Figure 3J, K). This is consistent with our previous findings in SMARCA4 deficient 
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cancers [32,33]. Taken together, these data demonstrate that cyclin D1 deficiency induced by 
SMARCB1 loss is a key determinant of palbociclib sensitivity in ATRT. 
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Discussion  
Our study demonstrates that cyclin D1 protein deficiency in ATRT is caused by 
SMARCB1 loss at least in part through upregulation of MIR17HG, which is known to produce 
mature miRNAs targeting cyclin D1. Furthermore, we establish that this cyclin D1 deficiency in 
ATRT cells contribute to their susceptibilities to CDK4/6 inhibition.  
Previous data show that ATRT and SCCOHT are both driven by biallelic inactivation of 
one of the key SWI/SNF components. As described in the introduction, these two cancers, while 
arising from two distinct organs, closely resemble each other at the histopathological, genetic and 
epigenetic levels [30]. Furthermore, both cancers exhibit cyclin D1 deficiency caused by their 
driver mutations. In SCCOHT, this is at the level of direct transcriptional regulation – SMARCA4 
loss results in strong suppression of CCDN1 expression [33]; In ATRT, SMARCB1 loss causes 
altered post-transcriptional regulation of cyclin D1 mediated by MIR17HG.  Similar to SCCOHT, 
ATRT cells are also highly sensitive to CDK4/6 inhibition due to their cyclin D1 deficiency, 
supporting the notion whereby critically low oncogene levels, caused by loss of a driver tumor 
suppressor, may also be exploited therapeutically. 
In addition to MIR17HG, other SMARCB1 target genes may also contribute to the cyclin 
D1 dysregulation in ATRT. We also recognize that this cyclin D1 deficiency likely does not 
promote cell cycle progression and drive these cancers and may be compensated by other cell cycle 
regulators, which remains to be investigated. miRNAs encoded by MIR17HG are known as 
oncogenic, with expression frequently upregulated in cancers [58]. Thus, it is possible that 
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MIR17HG upregulation by SMARCB1 loss independently contribute to the development of ATRT. 
Since the best characterized tumor suppressor targets PTEN and BIM are not regulated by 
MIR17HG in ATRT cells, the role of MIR17HG in ATRT tumorigenesis needs further studies.  
 Our data suggest that ATRT tumors may be responsive to CDK4/6 inhibitors as single 
agents due to their deficiency in (and hence heightened dependence on) cyclin D1 expression. 
Furthermore, we show that ATRT patient tumors were generally RB-proficient and p16-deficient, 
a known profile associated with positive responses to CDK4/6 inhibitors [34–36]. It has been show 
that pan-CDK inhibitors have promising efficiencies in targeting ATRT in preclinical studies 
[56,57], although with the rationale that these tumors have activated cyclin D1 caused by 
SMARCB1 loss based on previous studies in MRT. Independently supporting our model, 
overexpression of cyclin D1 has been observed in rhabdoid tumor resistant to pan-CDK inhibitor 
in mouse [56]. In addition, a recent phase I dose-escalation study in 13 ATRT patients showed that 
the two patients who received more than 4 cycles (3-weeks-on/1-week-off) of ribociclib (another 
FDA-approved CDK4/6 inhibitor similar to palbociclib) treatment achieved stable disease and 
remained stable on treatment for more than 20 months of follow-up [59]. Considering that all 
patients enrolled had progressed on previous standard therapy and the other 11 patients only 
received 1 or 2 cycles of ribociclib [59], these results support the anti-tumor activities of CDK4/6 
inhibitors in ATRT patients.  
It is also important to identify biomarkers of drug responses to improve the potential 
clinical utility of CDK4/6 inhibitors in treating ATRT. Our in vitro data suggest that cyclin D1 
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expression itself may be a potential biomarker - forced cyclin D1 overexpression in ATRT cells 
resulted in resistance to palbociclib. While our IHC results indicate an overall cyclin D1 deficiency 
in ATRT patient tumors, variable cyclin D1 expression were observed among these cases. This 
could potentially be due to the differential cyclin D1 expression in ATRT subtypes [10,13,14], 
which may be determined by a different cell of origin in brain and/or the age of patients of these 
subgroups [13]. This warrants further investigations. In addition, combination of CDK4/6 
inhibition with other approaches showing efficacies in ATRT such as high-dose chemotherapy and 
focal radiation [60] may also be explored. Indeed, it has been shown that palbociclib enhances 
radiation therapy effects in ATRT models [61].  
In summary, our study reveals an underlying mechanism for cyclin D1 deficiency in ATRT 
patient tumors, linking SMARCB1 to MIR17HG in regulating cyclin D1. Furthermore, our data 
suggest that this vulnerability of ATRT can be exploited therapeutically using the FDA-approved 
CDK4/6 inhibitors to improve survival of children affected by this fatal disease.  
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FIGURE LEGENDS 
Figure 1.  SMARCB1 loss leads to cyclin D1 deficiency in ATRT. (A, B), ATRT patient tumors 
express low levels of cyclin D1 and retain the RB-proficient/p16-deficient profile. 
Immunohistochemistry (IHC) analysis coupled with unbiased automated quantification [40] were 
performed on high-grade serous carcinomas (HGSC; n = 52), SCCOHT (n = 32) and ATRT (n = 
35) patient tumors for the expression of cyclin D1, p16 and RB. Representative images of the IHC 
analysis (A) and quantification results (B) are shown. Bar 50 µm; non-parametric Mann–Whitney 
test, ** p < 0.01, **** p < 0.0001; ns, not significant. Error bars show s.e.m. (C) Western blot 
analysis of indicated proteins in a panel of NHA and 7 ATRT cell lines. (D) Expression of cyclin 
D1 and p16 in indicated ATRT cell lines with or without SMARCB1 restoration. (E) Expression 
of cyclin D1 NHA cells with or without expression of shRNAs targeting SMARCB1. HSP90 
served as loading control. 
 
Figure 2. MIR17HG contributes to SMARCB1-mediated cyclin D1 regulation in ATRT. (A) 
Venn diagrams of the number of genes upregulated or downregulated in RNA-Seq analysis with 
BT12 and CHLA-06 upon SMARCB1 restoration (n=3, fold-change>2.5, adjusted p <0.01). (B) 
Overlapping genes in SMARCB1 common regulated genes from RNAseq data in ATRT cells and 
genes that showed SMARCB1 occupancy within 100 kbp from their TSS in SMARCB1-proficient 
HeLa cells from a previous study [50]. Red-labeled genes are upregulated and blue are 
downregulated. (C) RT-qPCR analysis of MIR17HG mRNA in BT12 and CHLA-06 cells with or 
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without SMARCB1 restoration. (D) ChIP-seq data in vicinities of the MIR17HG locus indicate 
enhanced SMARCB1 binding at promoter regions in indicated cell lines. (E) SMARCB1 ChIP-
PCR for regions at MIR17HG promoter and upstream control site in BT12 cells with or without 
SMATCB1 restoration. Locations of these two sites are indicated as blue and green bars in (D). 
IgG served as an antibody control. (F) RT-qPCR analysis of MIR17HG and CCND1 in BT12 and 
CHLA-06 cells expressing shRNAs targeting MIR17HG. (G) Cyclin D1 protein expression in 
BT12 and CHLA-06 cells expressing shRNAs targeting MIR17HG. (H) RT-qPCR analysis of 
miR-19a and CCND1 expression in BT12 and CHLA-06 cells expressing SMARCB1 or/and 
MIR17HG. miR-19a is a mature miRNA generated from MIR17HG. miR-19a expression was 
normalized to U6 and CCND1 mRNA was normalized to GAPDH. (I) Cyclin D1 protein 
expression in BT12 and CHLA-06 cells expressing SMARCB1 or/and MIR17HG. HSP90 serves 
as loading control in western blot results. (J) Expression of CCND1 and MIR17HG mRNA in 
indicated subtypes of ATRT patient tumors from a published microarray study [10]. (K) A 
schematic diagram for MIR17HG mediated cyclin D1 regulation by SMARCB1 in ATRT. Two-
tailed t-test. Error bars show SD, * p < 0.05, *** p < 0.001. 
 
Figure 3. Cyclin D1 deficiency underlies sensitivity to CDK4/6 inhibition in ATRT. (A) 
Colony formation assay of NHA control or ATRT (BT12 and CHLA-266) cells cultured in the 
absence or presence of palbociclib for 10–14 days. (B) Cell viability assay of ATRT cells (BT12, 
CHLA-266, CHLA-06, CHLA-05) and NHA. Cells were treated with palbociclib for 6 days and 
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subjected to a CellTiter-Blue assay. (C) Levels of pRB-S795 in cells treated with palbociclib at 0 
nM, 100 nM or 300 nM for 24h were analyzed by western blotting. HSP90 served as a loading 
control. (D,E) Efficiency of palbociclib in suppressing tumor growth in an orthotropic mouse 
model of ATRT. CHLA-06 cells expressing pLX317-Luciferase were intracranially engrafted into 
brains of NSG mice. After tumor establishment, mice were treated with vehicle for up to 18 days 
(reached endpoint due to tumor burden) or palbociclib (150 mg/kg) for 31 days. Tumor burden in 
live animals was visualized using an in vivo imaging system. Tumor-related luminescence images 
of representative mice (D) and luminescence fold change over time (E) of all animals (control, n 
= 4; palbociclib treated, n=6; two-way ANOVA, ***P < 0.001) are shown. Radiance 
(p/sec/cm2/sr), color scale (Minimum = 2.6 x 107, Maximum = 2.6 x 108). (F–H) Cell viability 
assay of CHLA-06 cells (F) and colony formation assay of BT12 cells (H) stably expressing 
control vector, CDK4 or CCND1 treated with indicated concentration of palbociclib. (G–I) Levels 
of pRB-S795, CDK4 and cyclin D1 were determined by western blot. (J) Colony formation assay 
of BT12 cells expressing shRNAs targeting cyclin D1 treated with palbociclib at 33 nM. (K) Levels 
of pRB-S795 and cyclin D1 were determined by western blot. HSP90 served as loading control. 
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SUPPLEMENTARY MATERIAL ONLINE 
 
Supplementary material and methods 
 
Figure S1. SMARCB1 restoration suppresses growth of ATRT cells 
 
Figure S2.  mRNA expression of CCND1 in ATRT cells with SMARCB1 restoration 
 
Figure S3. MIR17HG knock down in BT16 cells 
 
Figure S4.  miR-17/19a knock down in BT12 and CHLA-06 cells 
 
Figure S5. MIR17HG knockdown has no clear effect on expression of PTEN and BIM in ATRT 
cells 
 
Figure S6. MIR17HG and CCND1 mRNA expression in NHA and ATRT cells 
 
Table S1. Genes significantly regulated by SMARCA4 restoration in CHLA-06 and BT-12 cells 
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